symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BNTC,3.37,1.031455,594744,8584839,0.045,1.86-9.01,0.04,Benitec Biopharma Inc.,USD,0001808898,US08205P1003,08205P100,NASDAQ Capital Market,NASDAQ,Biotechnology,https://benitec.com,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.","Dr. Jerel A. Banks M.D., Ph.D.",Healthcare,US,18,510 780 0819,3940 Trust Way,Hayward,CA,94545,4.60235,5.63235,https://financialmodelingprep.com/image-stock/BNTC.png,2014-06-24,False,False,True,True,False
